0,1,2,3,4,5,6,7
Table 6.2.5.1:  Overview of all four randomised trials for adjuvant surgical bed radiation therapy after RP*,,,,,,,
Study,n,"Inclusion 
criteria",Randomisation,"Definition of 
BCR PSA (ng/
mL)","Median 
FU (mo)","Biochemical 
Progression-
free survival","Overall 
survival"
"SWOG 8794 
2009 [913]",431,"pT3 cN0 ± 
involved SM","60-64 Gy vs. 
observation",> 0.4,152,"10 yr.: 53% vs. 
30% 
(p < 0.05)","10 yr.: 
74% vs. 
66% 
Median 
time: 
15.2 vs. 
13.3 yr., 
p = 0.023"
"EORTC 
22911 2012 
[914]","1,005","pT3 ± 
involved SM 
pN0 pT2 
involved SM 
pN0","60 Gy vs. 
observation",> 0.2,127,"10 yr.: 60.6% 
vs. 41%
(p < 0.001)","81% vs. 
77% n.s."
"ARO 96-02 
2014 [912]",388,"pT3 (± 
involved SM) 
pN0 PSA 
post-RP 
undetectable","60 Gy vs. 
observation","> 0.05 + 
confirmation",112,"10 yr.: 56% vs. 
35% 
(p = 0.0001)","10 yr.: 
82% vs. 
86% n.s."
"FinnProstate 
Group 2019 
[915]",250,"pT2,R1/ 
pT3a","66.6 Gy vs. 
observation  
(+ SRT)","> 0.4 (in 2 
successive 
measurements)","112 vs. 
103 
(patients 
alive)","10 yr.: 82% vs. 
61% 
p < 0.001","10 yr.: 
92% vs. 
87% n.s."
